Medicine details

ImageNaproxen Plus
NameNaproxen Plus
DosageTablet
Generic NameEsomeprazole + Naproxen
Classes Analgesic / Pain Killer
Central Nervous System Agent
NSAID
Diseases Ankylosing Spondylitis
Arthritis
Inflammatory Disease
Ulcer
CompanyZenith Pharmaceuticals Ltd.

Drug Package Details

Strength20 mg + 375 mg
Storage Condition
Origin CountryBangladesh
Commercial Pack30
Price per pack240.00
Cost per pack211.20
Package unit10 tabs strip
Price per unit8.00
Cost per unit7.04
Discount0
Coupon
Remarks

Esomeprazole + Naproxen

Esomeprazole + Naproxen is a combination medication comprising of esomeprazole- a proton pump inhibitor that reduces the production of gastric acid, and naproxen- a non steroidal anti-inflammatory drug.

Esomeprazole + Naproxen is indicated for the following conditions-

  • osteoarthritis
  • rheumatoid arthritis
  • ankylosing spondylitis
  • Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: The dosage is one tablet twice daily of Esomeprazole + Naproxen 375 mg naproxen and 20 mg of esomeprazole or 500 mg naproxen and 20 mg of esomeprazole.
  • Geriatric Patients: Use caution when high doses are required and some adjustment of dosage may be required in elderly patients.
  • Patients With Moderate to Severe Renal Impairment: Naproxen-containing products are not recommended for use in patients with moderate to severe or severe renal impairment (creatinine clearance <30 mL/min).
  • Hepatic impairment: Patients with mild to moderate hepatic impairment should be continuously monitored, and a possible dose reduction based on the naproxen component of Esomeprazole + Naproxen may be considered.
  • Esomeprazole + Naproxen is not recommended for use in children.
  • The tablets are to be swallowed whole with liquid. Do not split, chew, crush or dissolve the tablet. Esomeprazole + Naproxen should be taken at least 30 minutes before meals.

The most common adverse reactions associated with the medication include-

  • dyspepsia
  • gastritis
  • diarrhea
  • gastric ulcer
  • abdominal pain
  • nausea
  • Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke. Patients with known CV disease/risk factors may be at greater risk.
  • New onset or worsening of pre-existing hypertension. Blood pressure should be monitored closely during treatment with Esomeprazole + Naproxen
  • Esomeprazole + Naproxen should be used with caution in patients with fluid retention or heart failure
  • Serious gastrointestinal (GI) adverse events, which can be fatal. The risk is greater in patients with a prior history of ulcer disease or GI bleeding, and in patients at high risk for GI events, especially the elderly. Esomeprazole + Naproxen should be used with caution in these patients
  • Symptomatic response to esomeprazole does not preclude the presence of gastric malignancy
  • Atrophic gastritis has been noted on biopsy with long-term omeprazole therapy
  • Treatment should be withdrawn when active and clinically significant bleeding from any source occurs
  • Renal papillary necrosis and other renal injury with long-term use. Use Esomeprazole + Naproxen with caution in the elderly, those with impaired renal function, hypovolemia, salt depletion, heart failure, liver dysfunction, and those taking diuretics, ACE-inhibitors or angiotensin II receptor antagonists.
  • Acute interstitial nephritis has been observed in patients taking PPIs. Not recommended for patients with moderate or severe renal impairment
  • Esomeprazole + Naproxen should not be used in aspirin hypersensitive patients
  • Serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal and can occur without warning. Discontinue Esomeprazole + Naproxen at first appearance of skin rash or any other sign of hypersensitivity
  • Elevated liver enzymes and, rarely, severe hepatic reactions. Discontinue use immediately if abnormal liver enzymes persist or worsen
  • Should be avoided in patients with severe hepatic impairment
  • Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin.
  • Proton pump inhibitor (PPI) therapy may be associated with increased risk of Clostridium difficile associated diarrhea.
  • Avoid concomitant use of esomeprazole with clopidogrel
  • Long-term and multiple daily dose PPI therapy is associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine
  • Interactions with diagnostic investigations for Neuroendocrine Tumors: Increases in intragastric pH may result in hypergastrinemia, enterochromaffin-like cell hyperplasia, and increased Chromogranin A levels which may interfere with diagnostic investigations for neuroendocrine tumors.
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs
  • Fetal toxicity: avoid drug starting at 30 weeks gestation

Contraindication

  • Known hypersensitivity to any component of VIMOVO or substituted benzimidazoles such as-
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

There is no known contraindication of Esomeprazole + Naproxen in terms of food and drinks.

Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery is contraindicated.